Accelerate to Discover

Back to filter

Related topics

From thousands of SVS to a handful of candidate genes

BioNano Genomics

Mar 1, 2018

Bionano’s Variant Annotation Pipeline (VAP) saves researchers valuable time (and frustration) by annotating structural...

Protectome analysis: A new selective tool for bacterial vaccine discovery

Acea Biosciences

Feb 28, 2018

New generation vaccines are in demand to include only the key antigens sufficient to confer protective immunity among...

Follow biological processes in vivo at the cellular level

Mauna Kea Technologies

Feb 27, 2018

Cellvizio Lab uses unique probe-based Confocal Laser Endomicroscopy technology. Watch this recorded webinar to learn...

A novel real time imaging platform to quantify Macrophage Phagocytosis


Feb 26, 2018

Phagocytosis is a specific form of endocytosis by which cells engulf and internalize solid matter. Macrophages,...

Mar 18, 2018

How to build the largest genome ever, in 3 easy steps

BioNano Genomics

Feb 23, 2018

Here we report the sequencing and assembly of the 32-gigabase-pair axolotl genome using an approach that combined...

Timelapse imaging of Drosophila melanogaster larva's central nervous system


Feb 22, 2018

Drosophila melanogaster is a well-established model organism to understand biological processes and study human...

High-throughput observation of molecular motor activity & dynamics


Feb 21, 2018

With LUMICKS’ C-Trap, it is possible to observe myosin activity,the processive motion, the binding kinetics along...

Mar 18, 2018

A novel real-time CTL assay to measure designer T-cell function against HIV Env(+) cells

Acea Biosciences

Feb 19, 2018

To increase the immunosurveillance in HIV infection, we used retroviral vectors expressing CD4-chimeric antigen...

Show all topics (10)

Expression profiling of ribosome biogenesis factors in AML patients

Apr 20, 2017

Acute myeloid leukemia (AML) is a heterogeneous disease. Prognosis is mainly influenced by patient age at diagnosis and cytogenetic alterations, two of the main factors currently used in AML patient risk stratification. However, additional criteria are required to improve the current risk classification and better adapt patient care. In neoplastic cells, ribosome biogenesis is increased to sustain the high proliferation rate and ribosome composition is altered to modulate specific gene expression driving tumorigenesis. Here, we investigated the usage of ribosome biogenesis factors as clinical markers in adult patients with AML. We showed that nucleoli, the nucleus compartments where ribosome production takes place, are modified in AML by analyzing a panel of AML and healthy donor cells using immunofluorescence staining. Using four AML series, including the TCGA dataset, altogether representing a total of about 270 samples, we showed that not all factors involved in ribosome biogenesis have clinical values although ribosome biogenesis is increased in AML. Interestingly, we identified the regulator of ribosome production nucleolin (NCL) as over-expressed in AML blasts. Moreover, we found in two series that high NCL mRNA expression level was associated with a poor overall survival, particular in elderly patients. Multivariate analyses taking into account age and cytogenetic risk indicated that NCL expression in blast cells is an independent marker of reduced survival. Our study identifies NCL as a potential novel prognostic factor in AML. Altogether, our results suggest that the ribosome biogenesis pathway may be of interest as clinical markers in AML.

Read more


Scientific paper

Get more info

Regina Fillerová

Field Application Specialist



+420 731 127 718

Send Message

Brand profile


Fluidigm is a Molecular and Single Cell Biology company that creates microfluidic-based chips and instrumentation for Life-Science research.

Related products

A new standard for high-throughput real-time PCR, end-point PCR and digital PCR

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic